Key catalysts lie ahead for Amgen, Argenx, Point Biopharma and Novo Nordisk.
The private group celebrates a double first for its mRNA-generated Car-T therapy in myasthenia gravis.
A look at biopharma’s most highly valued yet unpartnered assets features Karuna, Ventyx and regular bridesmaid Ascendis.
Pdufa dates are also set for Sarepta and UCB, and panels will discuss Leqembi and Beyfortus.
The second quarter promises big data reveals for Fibrogen, Travere, Argenx and Bavarian Nordic.
Some believe that blocking FcRn has TNF-like potential, and J&J, Immunovant and UCB are all hot on Argenx’s heels.
A crucial pivotal readout is approaching for the Belgian developer and Vyvgart, in a rare disease that represents the group’s riskiest move yet.
After years of slow progress, and with very little supporting clinical data, Abbvie pledges to push into a major Garp inhibition programme.
Moderna, Biomarin and Daiichi Sankyo will begin 2023 with important data reveals.